

Subscription Offer



Capital increase until September 30, 2025, by a minimum of CHF 5,500,000 / 2,200,000 registered shares and a maximum of CHF 8,000,000 / 3,200,000 registered shares

Issuer	InnoMedica Holding AG, Zug
Existing shares	15,998,808 fully paid-in registered shares with a nominal value of CHF 0.10 each
Capital increase	Increase by a minimum of 2,200,000 fully paid-in newly issued shares (nominal CHF 220,000) to a minimum of CHF 1,819,880.80 and a maximum of 3,200,000 fully paid-in newly issued shares (nominal CHF 320,000) to a maximum of CHF 1,919,880.80
Issue price	CHF 2.50 per share
Denomination	Minimum 6,000 new shares at a price of CHF 2.50 each (total CHF 15,000). Shareholders who subscribe below the minimum by exercising their subscription rights and wish to have their shares delivered to their securities account will cover the resulting bank fees.
Subscription right	Preferential subscription rights of the existing shareholders (no trading of subscription rights planned)
Subscription deadline	Until Tuesday, September 30, 2025, by postal mail to InnoMedica Holding AG, Dr. Martin Stähle, CFO, Gesellschaftsstrasse 16, 3001 Bern (copy by e-mail: ir@innomedica.com)
Deposit	Until Tuesday, September 30, 2025, for the subscription of new shares in the escrow account belonging to InnoMedica Holding AG, Kapitalerhöhung, 6300 Zug (UBS Switzerland AG, IBAN: CH89 0023 0230 8979 00D7 U).
Allocation	According to subscription rights. The allocation of unexercised subscription rights will be effected by the Board of InnoMedica Holding AG in the interests of the company and while ensuring equal treatment of shareholders.
Tradeability	Freely tradable registered shares, OTC (SIX SIS ISIN: CH0558973902)
Securitization	Confirmation of receipt of payment by InnoMedica Holding AG, delivery of the shares to the buyer's custody account after they have been paid up and after the capital increase has been entered in the commercial register.
Jurisdiction	Seat of InnoMedica Holding AG: Zug, Switzerland.
Dividend	The shares are entitled to dividends for the full fiscal year 2025.
Risks	Persons interested in the offer receive the Offering Prospectus, the Business Information 2025, as well as the Annual Report 2024 and the unaudited half-year financial statement 2025. The revised Consolidated Financial Statements 2024 according to IFRS will also be made available upon request. The undersigned is aware that he/she acquires the shares as a participation in the company with rights to a dividend. He/she cannot derive any rights from the submitted information to the subsequent performance (of the shares or the company).
Principal point of payment	UBS Switzerland AG, PWJ8-NT4, P.O. Box, 3001 Bern Phone: +41 (0)31 336 47 70, e-mail: norbert.mullis@ubs.com
Contact	Investor Relations, Phone +41 (0)44 383 88 22, e-mail: ir@innomedica.com

For this offer, a prospectus according to Art. 35 et seq of the Federal Act on Financial Services (FIDLEG) is issued, approved by SIX Exchange Regulation AG on August 15, 2025.

InnoMedica Holding AG

Gesellschaftsstrasse 16 | CH-3012 Bern | Phone: +41 (0)44 383 88 22 | info@innomedica.com | www.innomedica.com

Share Subscription Form



Capital Increase

Capital increase from CHF 1,599,880.80 to a minimum of CHF 1,819,880.80 and maximum of CHF 1,919,880.80

The undersigned

Name First name

Address ZIP/City

Phone E-mail

Custody account for the share transfer

Bank Custody Account No.

Bank account for eventual backpayment

Bank IBAN

participates in the capital increase 2025 as follows, within the capital spread specified in the Articles of Association as well as with regard to the decision by the Board of Directors on August 4, 2025, to issue a minimum of 2,200,000 and a maximum of 3,200,000 fully paid-in newly issued registered shares with a nominal value of CHF 0.10 each for an issue price of CHF 2.50 per share, and the Offering Prospectus of InnoMedica Holding AG dated August 2025:

Subscription of new shares

at CHF 2.50 each

x CHF 2.50 =
Number of new shares Total subscription CHF

Deposit on the escrow account
(UBS Switzerland AG)

IBAN: CH89 0023 0230 8979 00D7 U
Belonging to: InnoMedica Holding AG
Kapitalerhöhung, 6300 Zug
SWIFT: UBSWCHZH80A

The subscription is valid if until Tuesday, September 30, 2025,

- the signed form is transmitted by postal mail to the mailing address of InnoMedica (see below for details)
- the corresponding amount for the subscribed new shares is deposited in the escrow account of InnoMedica (see above for details)

Concurrent submissions by e-mail are welcome, but do not replace the mandatory postal submission.

The new shares are allocated in priority based on the subscription rights in possession of the undersigned and, additionally, based on the decision of the Board of Directors.

Current shareholders who would like to participate in the capital increase in accordance to or in excess of their subscription rights, must be entered accordingly in the share register with their shares or submit a bank statement of the shares in their securities account as of September 30, 2025 on the closing date. If existing shareholders use their subscription rights to subscribe for shares below the minimum number of shares, they must pay the transaction costs of CHF 64.86 to Swiss bank custody accounts (except UBS custody accounts exempt from transaction costs) and transfer the amount to the transaction account (IBAN: CH21 0023 5235 5668 5202 F in the name of InnoMedica Holding AG, 6300 Zug) by Tuesday, September 30, 2025.

Date Signature

Mailing address

InnoMedica Holding AG
Dr. Martin Stähle, CFO
Gesellschaftsstrasse 16, P.O. Box 2553, 3001 Bern

Copy by e-mail to: ir@innomedica.com

InnoMedica Holding AG

Gesellschaftsstrasse 16 | CH-3012 Bern | Phone: +41 (0)44 383 88 22 | info@innomedica.com | www.innomedica.com